SCHEMBL4895182

SCHEMBL4895182

Cc1cc2c(N3CCN(C(=O)CC(F)(F)F)CC3)nc(NC[C@@H](O)CO)nc2s1

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 15/20 0.54
IDH2 P48735 3/20 0.35
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4894675 0.90 P2RY12 (0.67) P2RY12
SCHEMBL4896684 0.90 P2RY12 (0.67) P2RY12
SCHEMBL4896996 0.90 P2RY12 (0.53) P2RY12IDH2
SCHEMBL4895006 0.90 P2RY12 (0.53) P2RY12IDH2
SCHEMBL4898753 0.87 P2RY12 (0.57) P2RY12CNR2
SCHEMBL4936951 0.86 P2RY12 (0.56) P2RY12CNR2
SCHEMBL4885638 0.80 P2RY12 (0.82) P2RY12CNR2
SCHEMBL4894358 0.80 P2RY12 (0.82) P2RY12CNR2
SCHEMBL4895061 0.80 P2RY12 (0.55) P2RY12IDH2CNR2
SCHEMBL4914232 0.79 P2RY12 (0.68) P2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194590-A1 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC 2008-08-14 US disclosed
US-20080194590-A1 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC 2008-08-14 US disclosed
US-20080194590-A1 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194590-A1 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors PFKP, PF4, P2RY4 P2RY12 20/4885IDH2 2475/4885CNR2 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.